MSD

Pembrolizumab/Lenvatinib

Biodrugs/ Drugs
Cancer
Lenvatinib plus Pembrolizumab for first Line Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma
3Phase III in Spain, 2Phase II in Spain, 1Phase I